Compare BIO & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIO | ROIV |
|---|---|---|
| Founded | 1952 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 14.1B |
| IPO Year | N/A | N/A |
| Metric | BIO | ROIV |
|---|---|---|
| Price | $316.23 | $21.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $358.50 | $24.31 |
| AVG Volume (30 Days) | 169.4K | ★ 8.4M |
| Earning Date | 02-12-2026 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,557,500,000.00 | $20,329,000.00 |
| Revenue This Year | $1.62 | N/A |
| Revenue Next Year | $2.26 | $741.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $211.43 | $8.73 |
| 52 Week High | $373.69 | $23.47 |
| Indicator | BIO | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 55.58 | 53.52 |
| Support Level | $300.26 | $21.15 |
| Resistance Level | $328.25 | $22.14 |
| Average True Range (ATR) | 7.57 | 0.65 |
| MACD | 2.39 | -0.13 |
| Stochastic Oscillator | 66.16 | 52.76 |
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.